J. Stern & Co. LLP Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

J. Stern & Co. LLP raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 57,538 shares of the medical research company's stock after acquiring an additional 3,198 shares during the period. Thermo Fisher Scientific makes up 2.8% of J. Stern & Co. LLP's investment portfolio, making the stock its 19th biggest holding. J. Stern & Co. LLP's holdings in Thermo Fisher Scientific were worth $29,933,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after buying an additional 196,864 shares in the last quarter. Capital World Investors raised its stake in shares of Thermo Fisher Scientific by 1.1% during the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after buying an additional 104,343 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock worth $4,075,540,000 after buying an additional 197,442 shares in the last quarter. Norges Bank purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $3,149,754,000. Finally, Franklin Resources Inc. raised its stake in shares of Thermo Fisher Scientific by 5.7% during the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock worth $2,935,377,000 after buying an additional 262,062 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on TMO shares. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Finally, Barclays dropped their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Five equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $610.27.

Thermo Fisher Scientific Trading Up 0.8 %

Shares of NYSE TMO traded up $3.40 on Tuesday, reaching $424.74. 1,131,619 shares of the company traded hands, compared to its average volume of 2,189,359. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The company has a 50 day moving average of $485.08 and a 200 day moving average of $525.48. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $160.33 billion, a PE ratio of 25.70, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the company posted $5.11 EPS. The company's quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.